Backed with $82 million and led by two of BioMarin’s former executives, Mendra plans to acquire rare disease assets and use ...

The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered, clinical-stage biopharma focused on mitochondrial biology and protein homeostasis, today announced it has won the ...

A Watertown biotech is suspending drug development and laying off essentially all of its workers in a bid to save cash and ...

FDA and EMA have issued 10 guiding principles for AI in drug development with the intended goal of ensuring safety and ...

Looking to overcome some of the limitations of existing obesity drugs, Alveus Therapeutics has debuted with nearly $160 million in hand and an impressive roster of executives ready to take the biot | ...

The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...

Our first biotech bi-weekly of 2026 is here with recent innovations in genomic drug discovery, organoid development and ADC characterization.

Edesa Biotech, Inc. has announced its financial results for the first half of 2025, highlighting a $15 million equity financing aimed at advancing its vitiligo drug candidate, EB06, an anti-CXCL10 ...

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

Uncover the systematic approach to biotech firm valuation using DCF. Equip yourself with the knowledge to gauge company ...

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...